Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

(2019) Josef Coresh et al.   Lancet Diabetes & Endocrinology

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

(2019) Hiddo J L Heerspink et al.   Lancet Diabetes & Endocrinology

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria

(2019) Sadayoshi Ito et al.   Clinical Journal of the American Society of Nephrology

Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?

(2019) Atsuhisa Sato   HYPERTENSION RESEARCH

The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases

(2019) Gang Wang et al.   Journal of Translational Medicine

Vascular and inflammatory mineralocorticoid receptors in kidney disease

(2019) Jonatan Barrera‐Chimal et al.   Acta Physiologica

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy

(2017) Shigehiro Katayama et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy

(2014) Masakazu Haneda et al.   Clinical and Experimental Nephrology

Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis

(2013) Nancy J. Brown   Nature Reviews Nephrology

Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension

(2012) GianLuca Colussi et al.   JOURNAL OF HYPERTENSION

Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan

(2008) L. Vogt et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY